JP6671364B2 - ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 - Google Patents

ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 Download PDF

Info

Publication number
JP6671364B2
JP6671364B2 JP2017523804A JP2017523804A JP6671364B2 JP 6671364 B2 JP6671364 B2 JP 6671364B2 JP 2017523804 A JP2017523804 A JP 2017523804A JP 2017523804 A JP2017523804 A JP 2017523804A JP 6671364 B2 JP6671364 B2 JP 6671364B2
Authority
JP
Japan
Prior art keywords
glycoprotein
dengue virus
subject
antibody
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017523804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500878A5 (cg-RX-API-DMAC10.html
JP2018500878A (ja
Inventor
バリック，ラルフ
ウィドマン，ダグラス
ヨーント，ボイド
ガリチョット，エミリー
ロイヤル，スコット
デシルヴァ，アラヴィンダ
スワンストローム，ジェシカ
Original Assignee
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル filed Critical ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル
Publication of JP2018500878A publication Critical patent/JP2018500878A/ja
Publication of JP2018500878A5 publication Critical patent/JP2018500878A5/ja
Application granted granted Critical
Publication of JP6671364B2 publication Critical patent/JP6671364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
JP2017523804A 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物 Expired - Fee Related JP6671364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462074053P 2014-11-02 2014-11-02
US62/074,053 2014-11-02
PCT/US2015/058610 WO2016070178A1 (en) 2014-11-02 2015-11-02 Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development

Publications (3)

Publication Number Publication Date
JP2018500878A JP2018500878A (ja) 2018-01-18
JP2018500878A5 JP2018500878A5 (cg-RX-API-DMAC10.html) 2018-12-13
JP6671364B2 true JP6671364B2 (ja) 2020-03-25

Family

ID=55858450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017523804A Expired - Fee Related JP6671364B2 (ja) 2014-11-02 2015-11-02 ワクチンおよび診断開発のための組換えデングウイルスについての方法および組成物

Country Status (12)

Country Link
US (2) US10398768B2 (cg-RX-API-DMAC10.html)
EP (1) EP3212672A4 (cg-RX-API-DMAC10.html)
JP (1) JP6671364B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170075775A (cg-RX-API-DMAC10.html)
CN (1) CN107207619A (cg-RX-API-DMAC10.html)
AU (1) AU2015338859A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017008952A2 (cg-RX-API-DMAC10.html)
CA (1) CA2966198A1 (cg-RX-API-DMAC10.html)
MX (1) MX2017005524A (cg-RX-API-DMAC10.html)
MY (1) MY179251A (cg-RX-API-DMAC10.html)
SG (1) SG11201703366RA (cg-RX-API-DMAC10.html)
WO (1) WO2016070178A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026845A1 (en) * 2016-08-01 2018-02-08 Inbios International, Inc. Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens
CN106632620B (zh) * 2016-11-29 2019-08-23 菲鹏生物股份有限公司 登革病毒重组抗原及其制备方法和应用
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
CN110568190A (zh) * 2019-08-30 2019-12-13 深圳国际旅行卫生保健中心 登革热病毒抗原、检测试剂、检测试纸、检测试剂盒及其使用方法
US12600752B2 (en) 2019-11-20 2026-04-14 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
WO2023178310A1 (en) * 2022-03-17 2023-09-21 The University Of North Carolina At Chapel Hill Compositions comprising modified flavivirus e glycoproteins and methods of making and using the same
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用
WO2024238948A2 (en) * 2023-05-17 2024-11-21 University Of Iowa Research Foundation Dengue virus serotype-specific modulation of t cell responses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
DK2054428T3 (da) * 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
BR112015032388A8 (pt) * 2013-06-26 2020-01-14 Univ North Carolina Chapel Hill glicoproteína e do vírus quimérico da dengue, seus usos, partícula de flavivírus, molécula de ácido nucleico isolado, e composições

Also Published As

Publication number Publication date
US20200230224A1 (en) 2020-07-23
CA2966198A1 (en) 2016-05-06
MX2017005524A (es) 2018-01-26
MY179251A (en) 2020-11-02
AU2015338859A1 (en) 2017-06-01
SG11201703366RA (en) 2017-05-30
WO2016070178A1 (en) 2016-05-06
CN107207619A (zh) 2017-09-26
BR112017008952A2 (en) 2018-01-16
US20170333548A1 (en) 2017-11-23
EP3212672A4 (en) 2018-04-25
EP3212672A1 (en) 2017-09-06
US10398768B2 (en) 2019-09-03
KR20170075775A (ko) 2017-07-03
JP2018500878A (ja) 2018-01-18

Similar Documents

Publication Publication Date Title
US10398768B2 (en) Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
US12600752B2 (en) Methods and compositions for recombinant dengue viruses or vaccine and diagnostic development
US11241491B2 (en) Methods and compositions for dengue virus serotype 4 epitopes
US20180125964A1 (en) Chimeric dengue virus e glycoproteins comprising mutant domain i and domain ii hinge regions
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
US10870682B2 (en) Methods and compositions for dengue virus vaccines
RU2376374C2 (ru) Вакцина против вируса лихорадки западного нила
CN102905725A (zh) 用于经典猪瘟的标记疫苗
WO2024025906A1 (en) Hcv antigens and antibodies
CN101287490B (zh) 对抗登革热病毒感染的疫苗接种
MX2008001978A (en) Vaccination against dengue virus infection
AU2012216852A1 (en) Vaccination against dengue virus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200303

R150 Certificate of patent or registration of utility model

Ref document number: 6671364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees